TY  - GEN
AB  - An analysis of new, FDA-approved molecular entities reveals dynamism in terms of new innovation. An assessment of the first patent for each drug reveals that the pharmaceutical industry, particularly large, established companies in North America, tend to dominate the field. Whereas inventors continue to found biotechnology companies at a steady rate, recent trends suggest these inventors more often come from the private sector.
AU  - Kinch, Michael S.
DO  - 10.34667/tind.28887
DO  - doi
ID  - 28887
KW  - Patents
KW  - Patents
KW  - Intellectual property
KW  - Patents
KW  - Marks
L1  - https://tind.wipo.int/record/28887/files/wipo_pub_econstat_wp_24.pdf
L2  - https://tind.wipo.int/record/28887/files/wipo_pub_econstat_wp_24.pdf
L4  - https://tind.wipo.int/record/28887/files/wipo_pub_econstat_wp_24.pdf
LA  - eng
LK  - https://tind.wipo.int/record/28887/files/wipo_pub_econstat_wp_24.pdf
N2  - An analysis of new, FDA-approved molecular entities reveals dynamism in terms of new innovation. An assessment of the first patent for each drug reveals that the pharmaceutical industry, particularly large, established companies in North America, tend to dominate the field. Whereas inventors continue to found biotechnology companies at a steady rate, recent trends suggest these inventors more often come from the private sector.
SN  - 2957-8256
T1  - Sources of Biopharmaceutical Innovation :An Assessment of Intellectual Property.
TI  - Sources of Biopharmaceutical Innovation :An Assessment of Intellectual Property.
UR  - https://tind.wipo.int/record/28887/files/wipo_pub_econstat_wp_24.pdf
ER  -